Pericarditis Market

Market Overview:

The 7 major pericarditis markets reached a value of US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.91% during 2024-2034.

The pericarditis market has been comprehensively analyzed in IMARC's new report titled "Pericarditis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pericarditis is a medical condition characterized by inflammation of the pericardium, the sac-like structure surrounding the heart. Depending on the intensity, the inflammation can be acute, occurring suddenly and persisting for a short period of time, or chronic, appearing slowly and lasting longer. The most common symptom of the ailment is chest pain, which can be sharp, stabbing, or aching in nature and is typically felt in the center or left side of the chest. Various other symptoms can include a low-grade fever, fatigue, shortness of breath, cough, a feeling of discomfort in the chest or abdomen, etc. In more severe cases, pericarditis can cause fluid to accumulate around the heart, leading to a condition called cardiac tamponade that can be life-threatening. The diagnosis of pericarditis involves a physical exam, a review of the patient's medical history, and diagnostic tests. Diagnostic procedures may include an electrocardiogram (ECG) to look for changes in the heart's electrical activity, a chest X-ray to monitor signs of fluid buildup, and blood tests to check for markers of inflammation. In some cases, additional imaging tests, such as echocardiogram and MRI, may be used to evaluate the heart and pericardium in more detail.

The rising incidences of viral, bacterial, and fungal infections, which can cause inflammation of the pericardium, are primarily driving the pericarditis market. In addition to this, the increasing prevalence of several associated factors, such as autoimmune disorders, chest traumas, usage of certain drugs like isoniazid and phenytoin, etc., is also bolstering the market growth. Furthermore, the widespread adoption of various medications, including colchicine and corticosteroids, for reducing inflammation and preventing future episodes of pericarditis is acting as another significant growth-inducing factor. Additionally, the escalating utilization of immunoglobulin therapy, which involves infusing the patient with a high dose of antibodies to help fight off infections or autoimmune disorders that may be causing the ailment, is also propelling the market growth. Besides this, the increasing application of cardiac MRI that provides detailed images of the pericardium and surrounding structures, allowing for accurate diagnosis and assessment of disease severity, is further creating a positive outlook for the market. Moreover, the emerging popularity of minimally invasive procedures, such as pericardial drainage, to provide immediate relief from symptoms and reduce the risk of complications, including cardiac tamponade, is expected to drive the pericarditis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pericarditis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for pericarditis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pericarditis market in any manner.

Recent Developments:

• In February 2024, Cardiol Therapeutics received orphan drug designation (ODD) from the FDA for its lead small molecule drug candidate, CardiolRx, in the treatment of pericarditis, including recurrent cases.
• In December 2023, a study called “Variants at the interleukin-1 gene locus and pericarditis” by deCODE genetics discovered sequence variants that are located in a genomic locus encoding interleukin-1 immune cytokines and are protective against pericarditis, offering valuable insights for future studies and the development of new treatment approaches.
• In November 2023, R-Pharm International, LLC announced a clinical trial to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis.
• In April 2023, a study by Wenguang Liu et al. proposed a combined strategy based on coadministration of lipo/pcircRNA and strontium ions-containing nanoparticles-encapsulated injectable hydrogel and nitric oxide (NO)-bearing liposome-loaded pericardial adhesive hydrogel patch for realizing intramyocardial gene/ion delivery and epicardial NO delivery to inhibit cardiomyocyte apoptosis and inflammatory response.

Key Highlights:

• The Lancet study shows an increased risk of pericarditis, particularly among young men between 18 and 25 years, after mRNA vaccination.
• The incidence of acute pericarditis in the general population is estimated at approximately 27.7 cases per 100,000 subjects per year, whereas the standardized incidence rate of hospital admissions for pericarditis is 3.32 cases per 100,000 person-years.

Drugs:

Arcalyst (Rilonacept) is an FDA-approved treatment for adults and children aged 12 years and older with recurrent pericarditis. It works by inhibiting interleukin-1 (IL-1), a proinflammatory cytokine involved in the autoinflammatory response associated with the condition.

Goflikicept (formerly RPH-104) is a heterodimeric fusion protein developed by TRPHARM. It is currently in Phase III clinical trials for the treatment of pericarditis. The drug molecule works on an IL-1 beta inhibitor mechanism.

CardiolRx, developed by Cardiol Therapeutics, targets recurrent pericarditis by inhibiting the inflammasome pathway, which plays a crucial role in inflammation. In preclinical studies, cannabidiol, the active pharmaceutical ingredient in CardiolRx, demonstrated significant effects in reducing pericardial effusion and thickness and suppressing key inflammatory markers such as IL-1β and IL-6 in a model of acute pericarditis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the pericarditis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the pericarditis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pericarditis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the pericarditis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the pericarditis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the pericarditis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of pericarditis across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of pericarditis by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of pericarditis by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of pericarditis by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with pericarditis across the seven major markets?
• What is the size of the pericarditis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of pericarditis?
• What will be the growth rate of patients across the seven major markets?
   

Pericarditis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for pericarditis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pericarditis market?
• What are the key regulatory events related to the pericarditis market?
• What is the structure of clinical trial landscape by status related to the pericarditis market?
• What is the structure of clinical trial landscape by phase related to the pericarditis market?
• What is the structure of clinical trial landscape by route of administration related to the pericarditis market?